Qubo Open the TerminalOpen the Terminal

$ cd /reports / lly

Asset reportStocksNovember 202621 slides

Eli Lilly

Lilly is winning the obesity market on volume. Q3 revenue grew 39% to $24.4B as volumes rose 53%, more than offsetting a 15% fall in prices. Its tirzepatide drugs (Mounjaro and Zepbound) now make up about 65% of revenue. Novo Nordisk still leads in pills: its Wegovy pill sold about $810M vs $184M for Lilly’s Foundayo. The open questions are how fast prices keep falling, whether Foundayo catches up, and when the next drug, retatrutide, arrives. Lilly trades at about 31x forward P/E, with a market value about 6x Novo’s.

Published 15 Nov 2026Eli Lilly LLYNext edition 1 Dec

SLIDE 01 / 21Cover of the Eli Lilly report

The first slides, as they appear in the reader.

How to read it.

Starter

Not included

Qubo Research is for subscribers, from Pulse.

Pulse · Edge

1 or 5 reports a month

1 with Pulse, 5 with Edge, plus previews and flash notes.

Apex

Library included

Every report, every edition and the archives. 5 custom reports a month.

Editions:Nov 2026Follow the series in the Terminal to get the next one.

Read it next to the live LLY chart.

Open the report in the Terminal: price, news and why it moves, on the same screen.

Open the TerminalOpen the Terminal

General research, the same for every reader: it does not take anyone’s situation into account and does not recommend buying, selling or holding any asset. No price targets. May contain errors.